GlassScriptPhysician profile
Landy M Morales
NPI 1043491715
$1,250.47
in general payments reported to CMS, 2019-2025
18 companies · $157 in 2025
The $157 reported for 2025 was more than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $412 · 2020: $72.72 · 2022: $110 · 2023: $300 · 2024: $198 · 2025: $157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $655.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $654.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $220.08 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $191.94 | 2019-2025 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $126.25 | 2019-2024 | Xarelto |
| Abbvie INC. | $125.14 | 2022-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $109.69 | 2019-2024 | Lifevest |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.68 | 2019-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $58.23 | 2022-2023 | Dificid |
| Vifor Pharma, INC. | $54.09 | 2019-2020 | |
| Dexcom, INC. | $45.81 | 2024-2025 | Dexcom G6 Transmitter |
| Portola Pharmaceuticals, LLC | $45.45 | 2019 | |
| Melinta Therapeutics, LLC | $33.85 | 2019 | |
| Mallinckrodt Hospital Products INC. | $31.16 | 2023 | Terlivaz |
| Daxor Corporation | $24.33 | 2023 | Bva-100 |
| Astrazeneca Pharmaceuticals LP | $22.63 | 2019 | |
| Allergan, INC. | $21.83 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $20.27 | 2019 | |
| Mallinckrodt Enterprises LLC | $19.82 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $19.22 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Landy Morales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.